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How does nephrocystin get into 
cilia?
An exciting recent development is the discovery that many 
mutations that cause polycystic kidney disease in humans 
and animals are in proteins that are localized to cilia or 
fl agella. But how do these proteins get to the cilia? Th e 
cell contains a structure located at the base of the cilia, 
and proteins destined to enter the cilia must be targeted 
to this basal body. Th e identifi cation of several proteins 
mutated in medullary cystic disease (nephronophthisis), 
the most common cystic disease of children, showed that 
most are localized to cilia or basal bodies. In a recent 
study, Schermer et al. showed that nephrocystin, a ciliary 
protein mutated in nephronophthisis type 1, is expressed 
in respiratory epithelial cells and accumulates at the base 
of cilia, overlapping with markers of the basal body area 
and transition zone. Th e protein includes Src homology 3 
domains in its structure, suggesting that it might interact 
with tyrosine-phosphorylated proteins. Th e authors showed 
that nephrocystin interacts with phosphofurin acidic cluster 
sorting protein 1 (PACS-1). Casein kinase 2-mediated 
phosphorylation of three critical serine residues within 
a cluster of acidic amino acids in nephrocystin mediates 
PACS-1 binding and is essential for colocalization of 
nephrocystin with PACS-1 at the base of cilia. Inhibition of 
casein kinase 2 activity abrogates this interaction and results 
in the loss of correct nephrocystin targeting. Th ese data 
suggest that casein kinase 2-dependent transport processes 
represent a novel pathway for targeting proteins to the 
cilia. It is important to examine whether this is a general 
phenomenon — that is, whether casein kinase 2 is required 
to phosphorylate all proteins destined to go to the basal 
body. If so, this phenomenon will be a major discovery in the 
cell biology of ciliogenesis. (EMBO J 2005; 24: 4415–4424)
Qais Al-Awqati
Defective planar cell polarity in 
polycystic kidney disease
Planar cell polarity (PCP) was fi rst discovered in fruit fl ies, 
wherein it was found that the hair spicules in the fl y were 
oriented in one direction and that some mutations disrupted 
the direction in which these hairs were pointing. Other 
studies showed the same phenomenon in the hair cells of 
the inner ear. Th e idea behind PCP is that an epithelial 
sheet or tubule (such as the renal tubule or gastrointestinal 
tract) is not uniform in the X–Y plane; rather, there is some 
characteristic that makes the ‘proximal’ cell diff erent from 
the ‘distal’ one. An additional characteristic of PCP is that 
when cells in the epithelial sheets divide, the axis of division 
of the separating chromosomes is a critical determinant of 
organ shape and size. Yet, other than the fact that the kidney 
has sheets of epithelia, there has not been any evidence for a 
program of PCP until recently. In a study reported in Nature 
Genetics, Fischer et al. investigated the lengthening of renal 
tubules. Th ey found that mitotic orientation of the dividing 
epithelial cells was parallel to the long axis of the tubule, 
demonstrating intrinsic planar cell polarization. Further, 
they studied a mouse model of polycystic kidney disease 
and found that mitotic orientations were signifi cantly 
distorted in polycystic kidney disease even in the tubules 
before they became cystic. Th ese results suggest that 
oriented cell division dictates the maintenance of constant 
tubule diameter during tubular lengthening, and that 
defects in this process trigger renal tubular enlargement and 
cyst formation. (Nature Genet 2006; 38: 21–23)
Qais Al-Awqati
Obesity is linked to risk for end-
stage renal disease
Th e relationship between obesity and kidney disease 
has been established, but this has been primarily done 
with the inclusion of diabetes and other risk factors. Few 
epidemiologic studies have examined whether being 
overweight is an independent risk factor for end-stage 
renal disease (ESRD). Previous studies with kidney biopsies 
found that obesity was associated with an increase in the 
incidence of glomerulopathy. Now, in a new study, Hsu 
and colleagues have found that obesity is associated with 
ESRD independent of other risk factors. Th e authors studied 
a historical cohort in 320 252 adult members of Kaiser 
Permanente. Members of this large integrated health-care 
delivery system in northern California volunteered for 
screening health checkups between 1964 and 1985 and 
had their height and weight measured. Th e authors found 
ESRD cases by matching data with the United States Renal 
Data System registry through 2000. A total of 1471 cases 
of ESRD occurred during the 8 347 955 person-years 
of follow-up. Higher weight was a risk factor for ESRD 
in multivariate models that adjusted for age, sex, race, 
education level, smoking status, history of myocardial 
infarction, serum cholesterol level, urinalysis proteinuria, 
urinalysis hematuria, and serum creatinine level. Compared 
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with persons who had normal weight (body mass index 
[BMI], 18.5–24.9 kg/m2), the adjusted relative risk for 
ESRD was 1.87 (95% confi dence interval [CI], 1.64–2.14) 
for those who were overweight (BMI, 25.0–29.9 kg/m2), 
3.57 (CI, 3.05–4.18) for those with class I obesity (BMI, 
30.0–34.9 kg/m2), 6.12 (CI, 4.97–7.54) for those with class 
II obesity (BMI, 35.0–39.9 kg/m2), and 7.07 (CI, 5.37–9.31) 
for those with extreme obesity (BMI ≥40 kg/m2). Higher 
BMI at baseline remained an independent predictor for 
ESRD aft er adjustment for baseline blood pressure level and 
diabetes. Th e study was limited in that primary analyses 
were based on single measurements of exposures, but it 
strongly suggests that obesity is a risk factor for ESRD. (Ann 
Intern Med 2006; 144: 21–28)
Lawrence Hunsicker
Cisplatin nephrotoxicity is 
mediated via the human organic 
cation transporter 2
Th e mechanism of the nephrotoxicity of the antineoplastic 
agent cisplatin remains unclear. In an article in the 
American Journal of Pathology, Ciarimboli et al. clearly 
identify the human organic cation transporter 2 (hOCT2) 
as the critical mediator for cisplatin nephrotoxicity in 
isolated human proximal tubules and off er a potential 
mechanism for reducing nephrotoxicity in clinical practice. 
Interaction of cisplatin with hOCT2 (expressed in the 
kidney) or hOCT1 (expressed in the liver) was investigated 
with the fl uorescent cation 4-[4-(dimethylamino)styryl]-
methylpyridinium in stably transfected HEK293 cells and 
in tissues physiologically expressing these transporters, 
human proximal tubules, and human hepatocyte couplets, 
cisplatin (100 µmol/l) inhibited transport via hOCT2-
HEK293 but not hOCT1-HEK293 cells. In human proximal 
tubules, cisplatin competed with basolateral organic 
cation transport, whereas it had no eff ect in hepatocytes. 
In hOCT2-HEK293 cells treated for 15 hours, incubation 
with cisplatin induced apoptosis, which was completely 
suppressed by contemporaneous incubation with the 
hOCT2 substrate cimetidine (100 µmol/l). Th us, the 
presence of hOCT2 was necessary to make HEK293 cells 
sensitive to cisplatin toxicity, and the toxic eff ect was 
prevented by simultaneous incubation with cimetidine. 
Th e presence of hOCT2 in renal proximal tubules explains 
cisplatin organ-specifi c toxicity. Th e combination of 
cisplatin with other substrates that compete for hOCT2 
off ers an eff ective option to decrease nephrotoxicity in the 
clinical setting. Th ese observations can now be translated 
to the bedside, where inert and nontoxic competitors 
for hOCT2 can be evaluated and hopefully reduce the 
considerable and oft en dose-limiting nephrotoxicity of 
cisplatin. (Am J Pathol 2005; 167: 1477–1484)
Detlef Schlöndorﬀ 
A BMP-7 antagonist expressed in 
the kidney
Once ESRD develops, it cannot be reversed by currently 
available therapy. Although administration of large doses of 
bone morphogenetic protein–7 (BMP-7) has been shown to 
repair established renal injury and improve renal function, 
the exact role of endogenous BMP-7 and its mechanism of 
action remain unclear. Yanagita et al. now show that the 
product of uterine sensitization-associated gene–1 (USAG1), 
a novel BMP antagonist abundantly expressed in the kidney, 
is the central negative regulator of BMP function in the 
kidney, and that mice lacking USAG-1 (USAG1–/– mice) are 
resistant to renal injury. USAG1–/– mice exhibited prolonged 
survival and preserved renal function in acute and chronic 
renal injury models. Renal BMP signaling, assessed by 
phosphorylation of Smad proteins, was signifi cantly 
enhanced in USAG1–/– mice with renal injury, suggesting 
that the preservation of renal function is attributable to 
enhancement of endogenous BMP signaling. Furthermore, 
the administration of neutralizing antibody against BMP-7 
abolished renoprotection in USAG1–/– mice. Th ese fi ndings 
indicate that USAG-1 plays a critical role in the modulation 
of renoprotective action of BMP, and that inhibition of 
USAG-1 is a promising means of development of novel 
treatment for renal diseases. (J Clin Invest 2006; 116: 70–79)
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